Abstract
Metastatic malignant melanom is one of the cancers that are most difficult to treat, with a median survival ranging from six to nine months. The reported five-year or longer survival rates are 1-2 %.
Melanoma accounts for nearly 350 deaths in the Czech Republic each yeasr. At first sight, this number does not seem dramatic, but it becomes considerably more significant in the light of the fact that most deths occur in the productive age group.
Dacarbazine that has been the standard first-line therapy for 35 years and severs as a reference in testing novel drugs induces therapeutic response in 15-20 % of patients.